Global Vasculitis Drugs and Companies Pipeline Review H1 2016

Vasculitis Treatment Pipeline Review H1 2016

PUNE, INDIA, August 30, 2016 / -- Summary
Vasculitis - Pipeline Review, H2 2016’, provides an overview of the Vasculitis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Vasculitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vasculitis and features dormant and discontinued projects.

Complete report details @

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
- The report provides a snapshot of the global therapeutic landscape of Vasculitis
- The report reviews pipeline therapeutics for Vasculitis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Vasculitis therapeutics and enlists all their major and minor projects
- The report assesses Vasculitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Vasculitis

Request a sample report @

Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Vasculitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Vasculitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @

Key points in table of content
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Vasculitis Overview 8
Therapeutics Development 9
Pipeline Products for Vasculitis - Overview 9
Pipeline Products for Vasculitis - Comparative Analysis 10
Vasculitis - Therapeutics under Development by Companies 11
Vasculitis - Therapeutics under Investigation by Universities/Institutes 12
Vasculitis - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
Vasculitis - Products under Development by Companies 17
Vasculitis - Products under Investigation by Universities/Institutes 18
Vasculitis - Companies Involved in Therapeutics Development 19
AnGes MG, Inc. 19
ChemoCentryx, Inc. 20
Cipla Ltd. 21
Coherus BioSciences, Inc. 22
F. Hoffmann-La Roche Ltd. 23
GlaxoSmithKline Plc 24
Hemostemix Ltd 25
Johnson & Johnson 26
K-Stemcell Co., Ltd. 27
Panacea Biotec Limited 28
Pfizer Inc. 29
Sandoz International GmbH 30
Teijin Pharma Limited 31
Vasculitis - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Target 33
Assessment by Mechanism of Action 35
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
ACP-01 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
belimumab - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
beperminogene perplasmid - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
CCX-168 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
immune globulin (human) - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
Monoclonal Antibodies to Antagonize GPR4 for Vascular Inflammation - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
Monoclonal Antibodies to Inhibit Glycoprotein Ib Alpha for Vasculitis and Glomerulonephritis - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
PF-1355 - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
rituximab biosimilar - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
rituximab biosimilar - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
rituximab biosimilar - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
sirukumab - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
Stem Cell Therapy for Thromboangiitis - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
Stempeucel - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
tocilizumab - Drug Profile 76
Product Description 76
Mechanism Of Action 76

Buy this report @

Norah Trent
+1 646 845 9349 / +44 208 133 9349
email us here